Cyclacel Pharmaceuticals, Inc. (CYCC):企業概要、財務及び戦略的SWOT分析

◆英語タイトル:Cyclacel Pharmaceuticals, Inc. (CYCC) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH37480FSA
◆発行会社(調査会社):GlobalData
◆発行日:2015年1月9日
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD300 ⇒換算¥33,300見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD600 ⇒換算¥66,600見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD900 ⇒換算¥99,900見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary

Cyclacel Pharmaceuticals, Inc. (Cyclacel Pharmaceuticals) is a pharmaceutical company. The company develops oral therapies for the treatment of cancer and other serious diseases. Its products include sapacitabine, seliciclib, and CYC116. Cyclacel Pharmaceuticals’ sapacitabine is the drug candidate used to treat the patients with acute myeloid leukemia; Seliciclib is an orally available, cyclin dependent kinase inhibitor; and CYC116 is an orally-active inhibitor of Aurora kinases A and B, and VEGFR2. It offers products for anti-infective, autoimmune, cardiovascular, ophthalmic and other non-oncology indications. The company has agreement with the U.S. Food and Drug Administration. Cyclacel Pharmaceuticals is headquartered in Berkeley Heights, New Jersey, the US.

Cyclacel Pharmaceuticals, Inc. Key Recent Developments

Nov 12, 2013: Cyclacel Reports Third Quarter 2013 Financial Results
Nov 06, 2013: Cyclacel Pharmaceuticals to Release Third Quarter 2013 Financial Results
Aug 14, 2013: Cyclacel Reports Second Quarter 2013 Financial Results
Aug 08, 2013: Cyclacel Pharmaceuticals to Announce Release of Second Quarter 2013 Financial Results
Jul 05, 2013: Cyclacel Pharmaceuticals to Present at the JMP Securities Healthcare Conference 2013

This comprehensive SWOT profile of Cyclacel Pharmaceuticals, Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Cyclacel Pharmaceuticals, Inc. including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Cyclacel Pharmaceuticals, Inc. – Key Information
Cyclacel Pharmaceuticals, Inc. – Overview
Cyclacel Pharmaceuticals, Inc. – Key Employees
Cyclacel Pharmaceuticals, Inc. – Key Employee Biographies
Cyclacel Pharmaceuticals, Inc. – Key Operational Heads
Cyclacel Pharmaceuticals, Inc. – Major Products and Services
Cyclacel Pharmaceuticals, Inc. – History
Cyclacel Pharmaceuticals, Inc. – Company Statement
Cyclacel Pharmaceuticals, Inc. – Locations And Subsidiaries
Cyclacel Pharmaceuticals, Inc. – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Cyclacel Pharmaceuticals, Inc. – Business Description
Cyclacel Pharmaceuticals, Inc. – Corporate Strategy
Cyclacel Pharmaceuticals, Inc. – SWOT Analysis
SWOT Analysis – Overview
Cyclacel Pharmaceuticals, Inc. – Strengths
Cyclacel Pharmaceuticals, Inc. – Weaknesses
Cyclacel Pharmaceuticals, Inc. – Opportunities
Cyclacel Pharmaceuticals, Inc. – Threats
Cyclacel Pharmaceuticals, Inc. – Key Competitors

Section 3 – Company Financial Performance Charts

Cyclacel Pharmaceuticals, Inc. – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Cyclacel Pharmaceuticals, Inc., Key Information
Cyclacel Pharmaceuticals, Inc., Key Ratios
Cyclacel Pharmaceuticals, Inc., Share Data
Cyclacel Pharmaceuticals, Inc., Major Products and Services
Cyclacel Pharmaceuticals, Inc., History
Cyclacel Pharmaceuticals, Inc., Key Employees
Cyclacel Pharmaceuticals, Inc., Key Employee Biographies
Cyclacel Pharmaceuticals, Inc., Key Operational Heads
Cyclacel Pharmaceuticals, Inc., Other Locations
Cyclacel Pharmaceuticals, Inc., Subsidiaries
Cyclacel Pharmaceuticals, Inc., Key Manufacturing facilities
Cyclacel Pharmaceuticals, Inc., Key Competitors
Cyclacel Pharmaceuticals, Inc., SWOT Analysis
Cyclacel Pharmaceuticals, Inc., Ratios based on current share price
Cyclacel Pharmaceuticals, Inc., Annual Ratios
Cyclacel Pharmaceuticals, Inc., Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Cyclacel Pharmaceuticals, Inc., Performance Chart
Cyclacel Pharmaceuticals, Inc., Ratio Charts

★海外企業調査レポート[Cyclacel Pharmaceuticals, Inc. (CYCC):企業概要、財務及び戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Akuo Energy SAS:企業のM&A・提携動向(エネルギー分野)
    Summary Akuo Energy SAS (Akuo Energy) is a power generation company that develops, finances, builds and operates renewable energy power plants. It undertakes green power generation projects across the entire project management life cycle. The company generates power using renewable energy sources su …
  • CNA Group Ltd. (5GC):企業概要、財務及び戦略的SWOT分析
    Summary CNA Group Ltd. (CNA) is a control and automation solution provider. The company provides services such as information communication technology; infrastructural, mechanical, electrical and plumbing works; and sustainable solutions. It operates with design and construction of infrastructural w …
  • Nucor Corporation:企業の戦略・SWOT・財務分析
    SummaryNucor Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findi …
  • GENEWIZ, Inc.:企業のM&A・提携動向(医療機器分野)
    Summary GENEWIZ, Inc. (GENEWIZ) is a genomics service company that provides research services. The company offers research in the areas of DNA sequencing, regulatory services, gene synthesis, molecular biology, genomics services, next generation sequencing, and bioinformatics. It provides regulatory …
  • RuiYi Inc.(製薬・医療分野):企業M&A動向
    Summary RuiYi Inc. (RuiYi) is a pharmaceutical company. The company discovers and develops biologic therapeutics for healthcare market. Its products include RYI-008, RYI-018, Avatar, and Kirin. The company’s RYI-008 is a monoclonal antibody used in the treatment of rheumatoid arthritis. Its product …
  • Xylem Water Solutions Global Services AB:企業の戦略的SWOT分析
    Xylem Water Solutions Global Services AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • ReputationDefender, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' ReputationDefender, Inc. Merger …
  • Edward Hospital & Health Services(製薬・医療分野):企業M&A動向
    Summary Edward Hospital & Health Services (EH & HS) is a healthcare service provider. The hospital provides medical specialties and various healthcare programs. It provides services such as, anxiety disorders, aortic aneurysm, aortic aneurysm screening (thoracic and abdominal), aortic stenosis, arrh …
  • The Acibadem Healthcare Group:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' The Acibadem Healthcare Group M …
  • Ahlstrom Corporation:企業のM&A・提携・投資分析
    Ahlstrom Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Ahlstrom Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • McLaren Health Care Corp:企業のM&A・提携動向(医療分野)
    Summary McLaren Health Care Corp (MHCC) is a healthcare service provider that offers home care, medical supplies and health insurance services. The center offers services in the fields of bariatrics, medical library, behavioral health, medical supplies and equipment, blood conservation, neuroscience …
  • Petrotec AG (PT8):企業の財務及び戦略的SWOT分析
    Summary Petrotec AG (Petrotec) is a biodiesel manufacturing company that manufactures biodiesel using its technology on the basis of residual and waste materials such as used cooking oil. The company’s by-products include glycerin, fatty acids, biodiesel polymer. Petrotec’s technology is able to pro …
  • Medical Resources, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Medical Resources, Inc. Mergers …
  • Yeda Research and Development Company Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Yeda Research and Development Company Ltd (Yeda), a subsidiary of Weizmann Institute of Science is a technology transfer company that provides research and science education. The company identifies and assesses research projects with commercial potential, protects the intellectual property o …
  • CITIC Resources Holdings Limited (1205):企業財務及び戦略的SWOT分析
    Summary CITIC Resources Holdings Limited (CITIC) is an oil and gas company that offers strategic natural resources and key commodities. The company offers Aluminium Smeltings that operates the PAS which produces alumina and aluminium ingots. Its Coal Segment comprises of operation of coal mines and …
  • Solasia Pharma KK (4597)-製薬・医療分野:企業M&A・提携分析
    Summary Solasia Pharma KK (Solasia Pharma) formerly JapanBridge Inc is a healthcare service provider that provides patient access to Western oncology therapies. The company develops and commercializes oncology therapies and cancer supportive care products. Its products include transdermal system whi …
  • TOTAL S.A.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' TOTAL S.A. Mergers and Acquisit …
  • Prudential Financial Inc:戦略・SWOT・企業財務分析
    Prudential Financial Inc - Strategy, SWOT and Corporate Finance Report Summary Prudential Financial Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • SPR Coffee:企業の戦略・SWOT・財務分析
    SummarySPR Coffee - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findings - D …
  • Ziarco Pharma Ltd:企業のM&A・提携動向(医療分野)
    Summary Ziarco Pharma Ltd (Ziarco) is a clinical-stage biotechnology company that focuses on the development of drugs for the treatment of dermatological and inflammatory diseases. The company’s lead compound includes ZPL-389, an oral histamine H4 receptor antagonist which is intended for the treatm …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆